CYP2D6

CYP2D6 Full Name

cytochrome P450, family 2, subfamily D, polypeptide 6

CYP2D6 Introduction

Introduction to the CYP2D6 Gene
The CYP2D6 gene, short for Cytochrome P450 Family 2 Subfamily D Member 6, is one of the most significant and extensively studied genes in the human genome regarding pharmacology. It encodes an enzyme that belongs to the cytochrome P450 superfamily, which is responsible for the oxidative metabolism of a vast array of endogenous compounds and exogenous substances, including approximately 25 percent of all clinically used drugs. Located on the long arm of chromosome 22, this gene is a critical determinant of how individuals respond to various medications, ranging from antidepressants and antipsychotics to beta-blockers and opioids. Unlike many other metabolic genes, CYP2D6 is unique because it is not inducible by external factors, meaning its enzymatic activity is almost entirely determined by an individual's genetic inheritance.

Figure 1. Strcuture of CYP2D6.

Phenotypic Classification and Metabolic Variations
One of the most vital aspects of CYP2D6 is the extreme variability in its enzymatic activity among different people. Based on the specific alleles inherited, individuals are categorized into four distinct metabolic phenotypes. Poor Metabolizers possess two non-functional alleles and lack any enzyme activity, leading to a high risk of drug toxicity. Intermediate Metabolizers have reduced activity, often carrying one functional and one non-functional or two sub-functional alleles. Extensive Metabolizers, also known as Normal Metabolizers, represent the majority of the population with standard enzyme function. Finally, Ultrarapid Metabolizers often carry multiple copies of the functional gene due to gene duplication, causing them to process drugs so quickly that therapeutic levels are never reached, or in the case of prodrugs, causing rapid conversion to toxic metabolites.

Clinical Implications in Pharmacogenetics The clinical significance of CYP2D6 cannot be overstated, particularly in the fields of psychiatry, cardiology, and pain management. For instance, the analgesic codeine is a prodrug that must be converted by CYP2D6 into its active form, morphine, to provide pain relief. An Ultrarapid Metabolizer taking codeine may experience life-threatening morphine toxicity, while a Poor Metabolizer will receive no pain relief at all. Similarly, many selective serotonin reuptake inhibitors used to treat depression are substrates of this enzyme. Understanding a patient's CYP2D6 genotype allows clinicians to practice precision medicine by adjusting dosages or selecting alternative medications to avoid adverse drug reactions or treatment failure, thereby improving patient safety and therapeutic outcomes.

Alternate Names for CYP2D6

CYP2D6; cytochrome P450, family 2, subfamily D, polypeptide 6; CPD6; CYP2D; CYP2DL1; CYPIID6; P450C2D; P450DB1; CYP2D7AP; CYP2D7BP